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A potential role for vitamin D as a therapeutic immunomodulator in tuberculosis (TB) has been recognised for over 150 years, but
has only recently returned to the centre of the research arena due to the increasing awareness of the global vitamin D deficiency
epidemic. As early as birth a child is often deficient in vitamin D, which may not only aﬀect their bone metabolism but also
modulate their immune function, contributing to the increased susceptibility to many infections seen early in life. Recent studies
have begun to explain the mechanisms by which vitamin D aﬀects immunity. Antimicrobial peptides are induced in conjunction
with stimulation of innate pattern recognition receptors enhancing immunity to particular infections. In contrast the role of
vitamin D within the adaptive immune response appears to be more regulatory in function, perhaps as a mechanism to reduce
unwanted inflammation. In this paper we focus on the eﬀect of vitamin D on immunity to TB. Where much of the attention has
been paid by past reviews to the role of vitamin D in adult TB patients, this paper, where possible, focuses on research in paediatric
populations.
1. Introduction
Immune responses to Mycobacterium tuberculosis (MTB) are
complex and remain incompletely understood. However,
with recent advances in the field of immunology, we have
learnt more about how MTB infects the human host and,
in turn causes disease. There is increasing epidemiological
evidence to support the role of vitamin D in the immune
response to tuberculosis (TB) [1]. A recent meta-analysis
included 7 studies with 531 participants and reported
that low serum vitamin D levels were associated with a
higher risk of active TB [1]. Additionally, an association
of TB with season has been observed in many countries,
including the UK where the incidence of TB is greater in
the spring/summer months. The decreased vitamin D levels
in the spring are thought to follow reduced sun exposure
during winter months (the circulating form of vitamin D, 25-
hydroxyvitamin D has an average half-life of 2–8 weeks [2–
5]). Similar seasonality of TB [6] has been noted in Europe
[4, 7], South Africa [8, 9], and India [10]. Dietary factors
also appear to influence vitaminD status and susceptibility to
TB. In a study of Asian UK immigrants, the vegetarian diet,
which is known to be low in vitamin D, was an independent
risk factor for TB [11]. The mechanisms by which vitamin
D may help to prevent or clear MTB infection and/or active
TB are not completely clarified to date, but studies that have
helped in the understanding of its role will be discussed in
this paper.
2. Historical Context: The Road to Rediscovery
Cod-liver oil was traditionally used in the treatment of tuber-
culosis in the late nineteenth and early twentieth centuries
[12]. The earliest case reports describing the eﬀects of cod-
liver oil in TB appeared in 1846 [13] and were followed
subsequently by numerous cases that supported the notion
that this dietary supplement could provide demonstrable
improvements in the health of TB suﬀerers [14]. Later in
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the nineteenth century, patients were frequently treated in
sanatoriums, which were built in the countryside, and were
designed to provide suﬀerers with therapeutic “fresh air”
and notably, sunshine. Indeed the clinical use of sunlight
exposure or “heliotherapy” gained significant momentum
following the award of the Nobel prize for medicine in 1903
to Niels Ryberg Finsen: “in recognition of his contribution to
the treatment of diseases, especially lupus vulgaris (tuberculosis
of the skin), with concentrated light radiation, whereby he has
opened a new avenue for medical science” [15].
It was not until later that vitamin D was discovered
as the active ingredient in cod-liver oil [17]. Charpy, a
physician from Dijon, France, appears to be one of the
earliest individuals to eﬀectively implement the clinical use of
vitamin D2 (calciferol) [18]. In 1945, he reported successfully
using the formulation to treat 20 patients with lupus vulgaris.
He obtained some “remarkable results” which were then
reproduced by others in Europe and around the world [18–
20]. By 1946 in London, Dr. Dowling and his colleagues had
also used calciferol on a number of patients. They reported
in the Proceedings of the Royal Society of Medicine that their
experience could “leave no room for doubt that calciferol in
adequate dosage will cure a substantial proportion of cases of
lupus” [20].
The first reference to successful treatment of pulmonary
TB with vitamin D appeared in the Lancet in 1947 [21].
The discovery by Alexander Fleming in 1928 of penicillin
and its subsequent mass production and distribution by
1945 revolutionised medical treatment of infectious diseases,
although not specifically TB, yet it appears that the benefits
of vitamin D were somewhat overlooked in the wake of the
antibiotic era [22].
3. Vitamin D Biochemistry
The term vitamin D encompasses a number of steroid-like
proteins: vitamins D2–D7. Vitamins D2 and D3 have known
physiological significance in humans, with both undergoing
hydroxylation steps to become active hormones in calcium
and phosphate metabolism [23]. Their chemical structure is
based on 4 steroid rings; 1 of which is broken. Vitamins D2
and D3 diﬀer only by the nature of their side chains [24].
The 2 forms of vitamin D can be obtained from the diet, but
predominantly, vitamin D is obtained in the D3 form, from
the action of UV light on a vitamin D precursor in the skin
[25].
Vitamin D3 undergoes two hydroxylation steps before
becoming an active hormone: the first step occurs in the
liver and results in the production of 25-hydroxyvitamin D
(25[OH]D) [26]. The “25” of 25-hydroxyvitamin D refers to
the location of a hydroxyl group on one of the side arms of
the steroid rings. This form of vitamin D must undergo a
further hydroxylation step to become physiologically active
in the form of 1-α,25-hydroxyvitamin D (1α,25[OH]2D). In
the past, it had erroneously been assumed that this second
hydroxylation step was only performed by the kidneys; how-
ever, it is now clear that a number of cells, particularly innate
immune cells such as monocytes and macrophages, possess
the machinery required to produce active 1α,25[OH]2D.
Indeed, since the discovery of vitamin D receptors (VDRs)
in macrophages, the role of 1α,25[OH]2D as an immune
modulator has become increasingly apparent [27].
In children, and neonates in particular, a C3-epimer of
the 25[OH]Dmolecule, 3-epi-25[OH]D3, often constitutes a
significant proportion of the total circulating 25[OH]D [28,
29]. It is therefore important, although not universal prac-
tice, to identify the proportion of the 3-epi-25[OH]D3 when
measuring 25[OH]D levels in children. The only method to
reliably do this is the liquid chromatography-tandem mass
spectroscopy method (LC-MS/MS) [28] enabling the epimer
measurement to be removed from the final result if required.
The RIA (radioimmune assay) method does not react with
the epimer and the high performance liquid chromatography
(HPLC) method cross-reacts with the epimer and causes
interference without being able to discriminate between the
isoforms making these methods unreliable when measuring
vitamin D levels in infants [28]. The 3-epi-25[OH]D3
diﬀers from 25[OH]D by the asymmetrical arrangement
of a hydroxyl group at the C3 position [28]. It is thought
that this epimer may be the result of immature vitamin D
metabolism and may display reduced eﬃcacy in calcium-
mediated bone metabolism [30]. Interestingly, the 3-epi-
25[OH]D3 form of vitamin D has a lower binding aﬃnity
for the VDR. However, this does not necessarily translate
into reduced biological eﬀects [31–33]. The overall impact of
the 3-epi-25[OH]D3 on immune health in infancy remains
unknown. However, we can speculate that supplementation
may be less eﬀective in the infant cohort, because when
the vitamin D supplement (cholecalciferol or ergocalciferol)
undergoes the first hydroxylation step, the infant produces
a large proportion of a physiologically less eﬀective epimer
of vitamin D, 3-epi-25[OH]D3. This may help to explain
why a recent large-scale vitamin D supplementation trial in
preterm neonates reported no significant eﬀect on overall
morbidity and mortality [34].
4. What Constitutes Vitamin D Sufficiency?
There is no agreed consensus on the optimal level for vitamin
D status in the adult [26, 35–38] and particularly what
constitutes vitamin D suﬃciency in childhood. In the UK
there are no up-to-date guidelines to define deficiency and
insuﬃciency [36]. It is true that with 25[OH]D levels below
<25 nmol/L children manifest clinical signs and symptoms
of rickets [37]. However, children can be diagnosed with
clinical rickets at higher 25[OH]D levels. Levels of 25[OH]D
above the 25 nmol/L cut-oﬀ may be associated with other
poor health outcomes [39], such as upper respiratory tract
infections [40] and bronchiolitis [41]. A recent paper in
the British Medical Journal summarises current opinion
regarding adult vitamin D endocrine levels (Table 1) [37].
However, as mentioned previously the situation is further
complicated in infancy by the presence of the C3-epimer
of 25[OH]D which can contribute to erroneously high total
25[OH]D levels [28].
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Table 1: Serum 25-hydroxyvitamin D (25[OH]D) concentrations,
health, and disease (modified from [37]).
25[OH]D
concentration
Vitamin D
status
Manifestation Management
<25 nmol/L Deficient
Rickets,
Osteomalacia
Treat with
high-dose
calciferol
25–50 nmol/L Insuﬃcient
Associated
with disease
risk
Vitamin D
supplementation
50–75 nmol/L Adequate Healthy Lifestyle advice
>75 nmol/L Optimal Healthy None
With increasing knowledge of the endocrine func-
tions of vitamin D and more recent evidence of possible
autocrine/paracrine functions, it is now important to also
consider the concentration of vitamin D required to drive
an appropriate immune response. At present this is not
known but in vitro experiments suggest that at 98 nmol/L
concentration IFNγ can induce antimicrobial expression and
can reduce growth of Mycobacterium tuberculosis whereas
levels of 45 nmol/L cannot [42].
Physiological ranges for circulating 25[OH]D3 can
extend to beyond 200 nmol/L which is much greater than
the considered average “norm” for a population. As a per-
spective, concentrations of 25[OH]D in nonhuman primates
have a median value of 170 nmol/L and a lowest value
>80 nmol/L [38], whereas modern humans in winter have
a median value of 40 nmol/L and a maximum value of
70 nmol/L [38], a similar amount to that of rodents. In
addition, a recent study of Masasai and Hadzabe hunter-
gatherer traditional populations in Tanzania showed that the
mean serum levels of 25[OH]D were 119 and 109 nmol/L,
respectively, and none were below 50 nmol/L. These higher
levels, only seen in Caucasian lifeguard populations that were
exposed to more than 3 hours of sun per day for more than
5 day/week for at least 3 months, may serve as targets for
further research [43].
With this lack of agreement on what levels of 25[OH]D
constitute suﬃciency, in turn there is variability in rec-
ommendations for supplementation. However a US study
of newborns found that 78% had levels of 25[OH]D <
75 nmol/L and 17% had levels < 30 nmol/L suggesting a need
for supplementation from birth [44]. The US Endocrine
Society proposes that infants and children aged 0-1 year
require at least 400 IU per day of vitamin D and that
children 1 year and older require at least 600 IU per day to
maximize bone health [5]. A recent study showed that in
pregnant women supplementation of 4000 IU/d was safe and
most eﬀective in achieving suﬃciency in women and their
neonates, whereas the current estimated average requirement
(200–400 IU/d) is comparatively ineﬀective at achieving
adequate circulating 25[OH]D concentrations [45]. In the
UK vitamin D supplementation for all mothers of breastfed
infants is recommended and in infants greater than 6months
who are taking less than 500mL of formulamilk per day [46].
US guidelines recommend that supplementation directly
to the breast fed (or partially breast fed) infant should
commence in the first few days of life [25]. Partly because
of the lack of agreement between health professionals,
but also for a plethora of other reasons, compliance to
these supplementation recommendations across countries
remains poor.
5. Vitamin D as an Immunomodulator
The role of 1α,25[OH]2D in calcium and phosphate
metabolism and bone health has been long established, but
its immunomodulatory function remains poorly defined.
In addition to TB as mentioned earlier, there is growing
evidence that lower 25[OH]D levels are associated with
a higher incidence of other infections, particularly of the
respiratory tract [40, 52–55]. However, there remains a large
degree of uncertainty in this area; for example, some studies
find that vitamin D deficiency is associated with worse
severity of infection in childhood [53, 56, 57], whilst others
do not [58]. To help understand these discrepancies, the role
of vitamin D in immunity, particularly with regards to TB, is
further discussed.
There is significant biological plausibility for a clinical
association between low 25[OH]D levels and infection with
many studies describing the direct eﬀect of 1α,25[OH]2D on
innate immunity [16, 59, 60]. Many immune cells express
the VDR, including T and B cells [61], dendritic cells
[62], as well as macrophages [63]. Initial studies found
that 1α,25[OH]2D stimulates antimicrobial activity [57, 58],
but it is only recently that the possible mechanism has
been described. Ligation of the innate immune pattern
recognition receptors, Toll-like receptors (TLRs) on human
macrophages, causes upregulation of the intracellular VDR
and vitamin D1 hydroxylase genes, resulting in induction of
cathelicidin [64] and/or β defensin [65], both of which are
potent antimicrobial peptides (Figure 1). It appears that this
action of 1α,25[OH]2D may be dependent on the presence
of interferon gamma (IFNγ) [42, 66] suggesting a link with
adaptive immunity.
In 1986 Rook et al. found that incubation of monocytes
with 1α,25[OH]2D inhibited growth of MTB [67]. Although
this appeared to be independent of IFNγ, the addition of
IFNγ along with 1α,25[OH]2D resulted in a synergistic
eﬀect on mycobacterial growth inhibition [67]. In addition
Denis showed that in the presence of IFNγ and TNFα,
1α,25[OH]2D promoted increased intramonocyte killing of
MTB [68]. These eﬀects are thought to be exerted through
the release of antimicrobial peptides as described previously
[65, 69]. Indeed, the more recent paper by Liu et al. in 2006
shows that monocyte TLR ligation promotes conversion
of 25[OH]D to 1α,25[OH]2D and subsequent cathelicidin
release. Cathelicidin induces fusion of the phagolysosome,
which is essential for the containment, degradation and
subsequent killing of MTB [64] (Figure 1).
It seems that 1α,25[OH]2D also exerts its eﬀects on
innate immune responses by the promotion of autophagy
[70–72] and the suppression of tissue remodelling and lung
matrix breakdown [73]. Autophagy is a potent mechanism
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Figure 1: Mechanism of vitamin-D-induced immunity to Mycobacterium tuberculosis (modified from [16]). Stimulation of monocyte Toll-
like receptors (TLR1/2) by Mycobacterium tuberculosis (MTB) results in transcriptional induction of the vitamin D receptor (VDR) and
1α-hydroxylase (CYP27B1). Circulating 25-hydroxyvitamin D (25[OH]D) enters the cell and is converted to 1,25-dihydroxyvitamin D
(1,25[OH]2D) by the CYP27B1 enzyme. VDR-bound 1,25(OH)2D then induces expression of cathelicidin and β-defensin 2 (DEFB4).
In addition 1,25(OH)2D induces autophagy and downregulating metalloproteinases (MMPs), all of which help in the formation of
phagolysosomes and the killing of Mtb. 1,25(OH)2D also aﬀects the adaptive immune system and leads to an upregulation of regulatory
responses and a skewing towards a Th2 response. IFNγ is thought to induce the expression of the CYP27B1 enzyme suggesting a feedback
mechanism between the innate and adaptive response to vitamin D.
by which the host defends against mycobacterial infec-
tion, by degradation of a cells’ own components through
the lysosomal machinery [74]. Fabri and Modlin have
shown that monocytes cultured in vitamin D suﬃcient
sera and stimulated with IFNγ display autophagy as well
as secrete antimicrobial properties against MTB [72]. It
has been shown in vitro that 1α,25[OH]2D downregulates
matrix metalloproteinases (MMPs) and upregulates tissue
inhibitor of metalloproteinase 1 (TIMP1) in peripheral
blood mononuclear cells (PMBCs) in the presence of live
MTB [73]. MTB induces significant pathological eﬀects
through tissue remodelling and breakdown of extracellu-
lar matrix in the lung, and therefore it is possible that
1α,25[OH]2D may protect the host against this eﬀects.
It appears that downstream adaptive immunity can
also be modified by 1α,25[OH]2D [27, 75, 76], which is
evidenced by its eﬀects on human B-cell diﬀerentiation [77]
and antigen presentation [78]. Interestingly 1α,25[OH]2D
has antiproliferative eﬀects on CD4+ T cells [79] and
appears to inhibit Th1 cytokine production [80–83], whilst
promoting T regulatory function [84], and potentially upreg-
ulating Th2 cytokine production [85]. Culturing peripheral
blood mononuclear cells from TB patients in the presence
of 1α,25[OH]2D, Vidyarani et al. recently showed that
1α,25[OH]2D suppressed IL-12p40 and IFNγ production
in response to MTB antigens [83]. However, for MTB
to be maintained in a latent state, Th1-cytokine-driven
granuloma formation is actually required, and inhibition of
Th1 cytokines could therefore be detrimental to the host.
Indeed, a recent study using in vitro analysis of sera of
patients with pulmonary TB has shown that coculture of T
cells with 1α,25[OH]2D reduces the number of Th1 cytokine
expressing cells (specifically IFNγ and TNFα) [86]. The
authors propose that 1α,25[OH]2D “may play a dual role in
the immunity against tuberculosis by eliminating infection
as well as reducing inflammation at the site of infection”.
The eﬀects of vitamin D on Th2 cytokine responses
are less well understood, and certainly how changes in the
Th2 cytokine profile may aﬀect MTB infection in humans
has not been extensively studied. We do know that the
classical Th2 cytokines, IL-4, and IL-13 are potent inhibitors
of autophagy, which is an essential immune pathway in the
host defence against MTB infection although in contrast
autophagy has been shown to be induced by vitamin D
through the innate response as mentioned earlier [64–
66]. Animal studies suggest that production of IL-4, is
upregulated in the presence of 1α,25[OH]2D [85]. Indeed,
Boonstra et al. [87] have demonstrated that 1α,25[OH]2D
induces Th2 cell development and IL-4, IL-5, and IL-10
production in vitro. However, it is prudent to say that
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the eﬀects of vitamin D on Th2 cytokine production remain
unclear [88], and how changes to the Th2 cytokine profile
may aﬀect the pathophysiology of MTB infection needs
further elucidation.
6. Vitamin D and Infant Immunity to TB
In children, infections remain a major cause of morbidity
and mortality around the world [89, 90]. Many epidemio-
logical studies have shown that vitamin D is associated with
respiratory disease and viral infections including HIV [91].
There is very little literature describing the role of vitamin
D in immunity to TB in infants one such paper examined
vitamin D status in children with active TB and found that
86% were vitamin D deficient (25[OH]D < 20 nmol/L) or
insuﬃcient (25[OH]D < 75 nmol/L) [92].
The predominant cytokine essential for mycobacterial
immunity is IFNγ as shown in studies of patients who lack
the IFNγ and IL-12 receptor that leads to a predisposition
to mycobacterial infections [93]. The dual role of IFNγ
in enhancing the eﬀects of vitamin D in vitro, although,
being in itself reduced by addition of vitamin D, may be
quite diﬀerent when considering a neonate. In neonates
NK production of IFNγ has a dominant role to play in
response to MTB antigens rather than T cells as observed
in older infants and adults [94]. There are many other
distinct qualities of the immature immune response, in
particular reduced Th1 adaptive responses and attenuated
innate immunity [95, 96] which suggests that vitamin D may
have diﬀerent eﬀects in the immune system of infants than
that of adults. In vitro supplementation of 25[OH]D in cord
blood cultures showed increased TLR-induced cathelicidin
expression suggesting that supplementation in neonates may
improve antimicrobial activity [44]. It is known that infants
and young children are particularly susceptible to severe TB
[97, 98] and therefore the role of vitamin D in childhood TB
warrants further investigation.
Trying to understand the varying eﬀects of BCG world-
wide one study has looked at the association of vitamin
D with BCG vaccination. Lalor’s recent observational study
of UK infants found that those that were BCG vacci-
nated had higher vitamin D levels at 3 and 9 months of
age, compared to unvaccinated controls [99]. Interestingly
infants with higher vitamin D levels had lower IFNγ
responses to theMycobacterium-tuberculosis-purified protein
derivative (MTB PPD). As previously discussed, in vitro,
1α,25[OH]2D) has been shown to have dual eﬀects by, on the
one hand, dampening Th1 responses [81], yet on the other
stimulating antibacterial peptide secretion to aid clearance of
MTB [64]. Traditionally IFNγ response to vaccination is used
as an indicatory of the eﬀectiveness of the vaccine. However,
Lalor suggests that in the context of BCG vaccination, a
dampened IFNγ response may be beneficial to the host, in
preventing unnecessary inflammation in response to the Mtb
PPD which needs to remain present to provide protection
against TB [99]. A recent animal study supports this finding
with reduced IFNγ and IL-17F gene expression in PPD-
stimulated blood of BCG vaccinated cattle after addition of
vitamin D [100].
7. It Is in the Genes
Genetic factors clearly play a role: specific vitamin D receptor
(VDR) polymorphisms are associated with a higher risk of
TB [101]. The association between TB incidence and other
polymorphisms varies widely across diﬀerent ethnic groups.
For example, the FokI ﬀ genotype of the VDR appears to
be most consistently associated with increased susceptibility
to TB among Asians, but not Africans [102], whereas the
tt genotype of TaqI has been shown in Gambian men to
be associated with a higher risk of TB [103]. No studies
have looked at VDR polymorphisms and incidence of TB in
children, but a recent Canadian study reported an association
between the FokI ﬀ genotype of the VDR and acute lower
respiratory tract infection in young children [104].
8. Vitamin D Supplementation and
TB Treatment
There are disparate reports in the literature regarding a
role of vitamin D supplementation in the treatment of
TB infection (Table 2). Early studies reported a favourable
response [47, 51] to vitamin D supplementation. In Jakarta
in 2006, Nursyam et al. randomised 67 patients and found
that 100% of the vitamin D group versus only 76.7% of
the placebo group had sputum conversion at 12 weeks
(P = 0.002) [47]. However, Wejse et al. found no eﬀect
of supplementation on disease outcome [49]. The study
addressed the use of 100,000 IU of vitamin D given as an
adjunctive treatment at the time of commencement of anti-
TB therapy, and again at 5 and 8 months after starting
treatment. The authors note that the dose may have been
insuﬃcient, and the response to vitamin D dependent on the
immune status of the individual patient [49].
A recent large-scale trial of vitaminD supplementation in
the treatment of adult TB was carried out by Martineau and
colleagues in London, UK [50]. Patients who were receiving
standard anti-TB chemotherapy and had been supplemented
with vitamin D displayed sputum clearance almost 1 week
earlier than those taking placebo (from 43.5 to 36.0 days).
However the diﬀerence between the intervention and control
group did not reach statistical significance. Intriguingly, in a
subset of patients with the TaqI VDR polymorphism, time
to sputum conversion was significantly quicker than that in
controls, indicating that these patients would benefit from
supplementation.
Prevention of TB with vitamin D supplementation is
still debated [13]. In one study TB contacts were given
a single dose of 100,000 IU vitamin D. In vitro analysis
revealed those receiving the supplement had enhanced
immunity to mycobacteria, demonstrated through ability of
participants’ whole blood to restrict luminescence in the
BCG-lux assay [95]. These promising laboratory results need
to be addressed in a Randomised Control Trial (RCT) to fully
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Table 2: Vitamin D single dose (dosage concentration not reported).
Subjects (n) Country Vitamin D supplement Findings Reference
Adult studies
TB patients with pulmonary TB
aged 15–59 (67)
Jakarta,
Indonesia
0.25mg per day for 6 weeks
100% of vitamin D group had sputum
conversion at 12 weeks after
supplementation versus 76.7% of the
placebo group
[47]
TB contacts (192) London, UK
2.5mg single dose vitamin
D2
Those given the vitamin D had enhanced
immunity to TB using the lux in vitro
assays but did not aﬀect IFNg production
after ESAT-6/CFP-10 stimulation
[48]
TB patients with pulmonary TB
(367, 136 completed trial in
vitamin-D-supplemented group,
145 completed in placebo group)
Bissau,
Guinea
Bissau
100,000 IU of vitamin D
given at time of anti-TB
treatment, then at 5 and 8
months later
No diﬀerences in clinical severity between
groups and no diﬀerences in mortality 12
months later
[49]
TB (146) London, UK
2.5mg vitamin D2 given at
time of Tb treatment plus
14, 28 and 42 days later
Those on Vitamin D supplementation
displayed sputum clearance at 36 days
after treatment versus 43.5 dayes but this
was not statistically significant but it did
significantly hasten sputum culture
conversion in participants with the tt
genotype of the TaqI vitamin D receptor
polymorphism
[50]
Paediatric studies
Children aged between 1.5 and
13 years of age with TB (24), 13
extra thoracic, 7 intrathoracic,
and 4 mixed
Egypt
Vitamin D single dose
unable to obtain
information regarding
(dosage concentration not
reported)
8 weeks after supplementation greater
clinical improvement was observed in
vitamin-D-supplemented group
[51]
NB: 25mg = 1,000 IU.
support these results. However, there is evidence that vitamin
D supplementation can have beneficial eﬀects on immune
health in general, and particularly in childhood. a RCT in
school children 6–18 years of age showed that oral vitamin D
supplementation reduced the incidence of influenza A [92]
and a further trial found promise in the use of vitamin D
supplementation in the prevention of recurrent pneumonia
in children between the ages of 1–36 months [105]. However
no specific recommendations exist for the use of vitamin
D supplementation to improve immune health outcomes in
childhood.
9. Future Directions
Recent reports suggest that vitamin D deficiency has become
a global health epidemic with 20–100% of US, Canadian, and
European elderly men and women being vitamin D deficient
[106]. Children and younger adults are equally at risk with
vitamin D deficiency common in Australia, the Middle
East, India, Africa, and South America [106]. Historically
humans probably obtained their vitamin D requirement
from prolonged sunlight exposure as “hunters and gather-
ers”. However, current lifestyle practices, particularly in the
developed world, often dictate infrequent sun exposure and
a subsequent propensity to deficiency, which is confounded
by diets low in vitamin D.
With the expanding evidence that vitamin D not only
aﬀects bone metabolism but also may play a large role in
immune modulation, these global statistics are worrying.
Even neonates at birth are often deficient in vitamin D and
if vitamin D can aﬀect immunity to many infectious diseases
including TB, then further research in this area is required.
A number of RCTs are currently under way to assess
the role of vitamin D in the treatment of tuberculosis and
the results are eagerly awaited [107–113]. Of particular
interest for child health professionals is the ongoing study in
California to determine whether a single oral dose of vitamin
D given to infants prior to BCG vaccination will enhance the
immune response to BCG vaccination [114].
This paper draws attention to the lack of quality research
exploring the role of vitamin D in TB or other infections
in early childhood. As we now begin to understand the
diﬀerences in immune function between adults and children
more must be done to address this cohort with respect to
vitamin D deficiency and potential benefits of vitamin D
supplementation.
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